CIK 0001228627 · Non-accelerated filer<br>Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113516358
- Phone
- (984) 884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,211,769
- in 7 filings, $50K under 10b5-1 plans
Net −$3,211,769. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Foundation Fighting Blindness Retinal Degeneration Fund −$2.8M Director sold 15% of stake
- Gagnon Robert E. −$177K Chief Financial Officer sold 7% of stake
- Magrath George −$145K Chief Executive Officer sold 2% of stake
- YERXA BENJAMIN R −$117K President sold 5% of stake
- SCHACHLE JOSEPH K −$17K Chief Operating Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Magrath George Chief Executive Officer | Sale | −28,258 | $3.90 | $110K | 2,010,636 |
| 2026-10-23 | SCHACHLE JOSEPH K Chief Operating Officer | Sale | −4,767 | $3.57 | $17K | 286,673 |
| 2026-10-23 | YERXA BENJAMIN R President | Sale | −7,669 | $3.55 | $27K | 696,437 |
| 2026-10-23 | YERXA BENJAMIN R President | Sale | −25,520 | $3.53 | $90K | 670,917 |
| 2026-10-23 | Gagnon Robert E. Chief Financial Officer | Sale 10b5-1 | −14,000 | $3.55 | $50K | 542,375 |
| 2026-10-23 | Magrath George Chief Executive Officer | Sale | −9,591 | $3.59 | $34K | 2,038,894 |
| 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund Director | Sale | −556,000 | $4.96 | $2.8M | 3,236,171 |
| 2026-09-09 | Magrath George Chief Executive Officer | Option exercise | +392,157 | $1.15 | $451K | 2,124,026 |
| 2026-09-09 | Magrath George Chief Executive Officer | Shares withheld for taxes | −75,541 | $5.97 | $451K | 2,048,485 |
| 2026-09-09 | Magrath George Chief Executive Officer | Option exercise · Warrant (right to buy) | −392,157 | 0 | ||
| 2026-09-08 | Gallagher Cam Director | Option exercise | +784,314 | $1.15 | $902K | 2,800,111 |
| 2026-09-08 | Gallagher Cam Director | Option exercise · Warrant (right to buy) | −784,314 | 0 | ||
| 2026-09-03 | Gagnon Robert E. Chief Financial Officer | Sale | −28,000 | $4.54 | $127K | 556,375 |
| 2026-07-23 | YERXA BENJAMIN R President | Sale | −7,429 | $2.97 | $22K | 704,106 |
| 2026-07-23 | SCHACHLE JOSEPH K Chief Operating Officer | Sale | −4,644 | $2.94 | $14K | 291,440 |
| 2026-07-23 | Magrath George Chief Executive Officer | Sale | −9,475 | $2.95 | $28K | 1,731,869 |
| 2026-07-23 | Gagnon Robert E. Chief Financial Officer | Sale | −7,783 | $2.95 | $23K | 584,375 |
| 2026-05-18 | Foundation Fighting Blindness Retinal Degeneration Fund Director | Sale | −1,700,000 | $4.35 | $7.4M | 3,792,171 |
| 2026-04-23 | YERXA BENJAMIN R President | Sale | −7,470 | $5.24 | $39K | 711,535 |
| 2026-04-23 | SCHACHLE JOSEPH K Chief Operating Officer | Sale | −4,697 | $5.22 | $25K | 296,084 |
Page 1 of 7 · 136 trades